Thermo Scientific HR Multi-Attribute Method for biopharma analysis

Importance of the Topic

The comprehensive characterization of biotherapeutic proteins is essential to ensure safety, efficacy and reproducibility in drug development and manufacturing. As protein‐based drugs become more complex, identifying and monitoring critical quality attributes (CQAs) early in discovery accelerates process optimization and supports Quality by Design (QbD) principles.

Goals and Overview

This study presents the High‐Resolution Multi‐Attribute Method (HR MAM), an integrated liquid chromatography–high resolution accurate mass (LC-HRAM) workflow for simultaneous peptide mapping, CQA quantitation and New Peak Detection (NPD). The goal is to replace multiple traditional assays (SEC, CEX, CE-SDS, ELISA) with a single high‐resolution mass spectrometry approach, reducing resource burden while delivering site‐specific molecular detail.

Methodology and Instrumentation

The HR MAM workflow comprises:

• Peptide generation by tryptic digestion and system suitability verification using a Pierce BSA Protein Digest Standard.
• Separation on Thermo Scientific Vanquish Horizon UHPLC with Accucore Vanquish C18+ columns for high reproducibility and peak capacity.
• Detection on a Q Exactive Plus Hybrid Quadrupole-Orbitrap mass spectrometer, operating at up to 140,000 resolution to resolve closely spaced isotopes and deamidated forms.
• Data processing in Thermo Scientific BioPharma Finder for peptide identification and targeted CQA selection.
• Routine monitoring and compliant quantitative reporting in Chromeleon Chromatography Data System, including automated NPD.

Results and Discussion

High‐resolution data enabled clear separation of deamidated and native peptides, avoiding misintegration at lower resolutions. Quantitation across ten replicates showed excellent precision for glycoforms, oxidations and other modifications (<5% variance). NPD reliably detected spiked standard peptides and low‐level host cell proteins (<0.015% abundance). Consistent results were observed on three separate instruments, demonstrating robustness for QC release.

Benefits and Practical Applications

• Consolidation of multiple assays into a single LC-MS workflow reduces time and cost.
• Site‐specific quantitation of over 30 CQAs supports detailed process control.
• New Peak Detection streamlines impurity screening and lot release.
• Fully compliant data handling from discovery to routine QC.

Future Trends and Possibilities

Advances in Orbitrap speed and software algorithms will expand multisite monitoring and real‐time analytics. Integration with AI‐driven data mining may further enhance unknown modification discovery. Extending HR MAM to glycoengineering and cell‐based modalities will broaden its impact in personalized biologics.

Conclusion

The HR Multi-Attribute Method provides a unified, high‐confidence platform for CQA characterization and purity testing of biotherapeutics. By leveraging high‐resolution mass spectrometry and automated software, it enhances analytical depth, streamlines workflows, and meets regulatory compliance from R&D to QC.

Reference

None provided in original document.